Featuring Christopher Moreau.
Algernon Pharmaceuticals is a publicly traded, Canadian clinical stage drug development company investigating multiple drugs for unmet medical needs with global market opportunities. Join CEO Christopher J. Moreau as he talks about the company’s unique drug development model including its anchor, ground-breaking clinical investigation of the psychedelic drug DMT as a possible new treatment for stroke.
12:50 pm
Main Stage
Nov 4
Featuring Christopher Moreau.
Algernon Pharmaceuticals is a publicly traded, Canadian clinical stage drug development company investigating multiple drugs for unmet medical needs with global market opportunities. Join CEO Christopher J. Moreau as he talks about the company’s unique drug development model including its anchor, ground-breaking clinical investigation of the psychedelic drug DMT as a possible new treatment for stroke.